Table 3.

Summary of clinical trials with fatigue as an outcome in SLE.

AuthorsData CollectionScaleInterventionFollowup, weeksNFindingsCountry
Greco, et al192004–2006FSSAcupuncture vs minimal needling5–624No difference detectedUSA
Avaux, et al212012–2013FSSExercise vs controls1245Clinically significant improvement*Belgium
Davies, et al22Published 2012FSSLow GI diet and LC diet vs placebo623Clinically significant improvement with GI diet*, but only statistically significant improvement with LC diet (did not meet MCID)UK
Bogdanovic, et al20Published 2015FSSAerobic and isotonic exercise660Clinically significant improvement*Serbia
Arriens, et al17Published 2015FSSFish oil vs PBO2650No differenceUSA
Strand, et al132007–2010FACIT-FatigueBelimumab or PBO52 (n = 865); 76 (n = 819)1684Clinically significant improvement*Multicenter
Petri, et al142010–2012FACIT-FatigueBlisibimod or PBO2457Clinically significant improvement*USA and Brazil
Uppal, et al12Published 2009VASStandard therapy ± infliximab (anchor not specified)2427No difference detectedKuwait
Merrill, et al11Published 2010VASAbatacept vs placebo (anchor not specified)52175Clinically significant improvement*Multicenter
Hartkamp, et al18Published 2010MFIDHEA vs PBO5260No difference detectedthe Netherlands
Lai, et al162009–2011FASPBO vs escalating doses of N-acetylcysteine1236Statistically significant improvementUSA
Merrill, et al152011–2014BFITabalumab vs PBO521124No difference detectedMulticenter
  • * Met MCID (therefore both statistically and clinically significant difference detected). MCID: minimal clinically important difference; FSS: Krupp Fatigue Severity Scale; GI: glycemic index; LC: low-calorie; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue Scale; PBO: placebo; VAS: visual analog scale; MFI: Multidimensional Fatigue Inventory; DHEA: dehydroepiandrosterone; BFI: Brief Fatigue Inventory; FAS: Fatigue Assessment Scale; SLE: systemic lupus erythematosus.